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Signaling via both vitamin D (VitD) and the renin-angiotensin system (RAS) plays 
important roles in physiological processes. Evidence has mounted linking 
cardiovascular disease to increased activity of the RAS and VitD deficiency. 
Although several studies have established functional relationships between the 
RAS and VitD, many aspects of their complex interaction remain unknown. In this 
issue of Atherosclerosis, Valcheva and colleagues show that defective VitD 
signaling can promote vascular damage by inducing premature senescence of 
smooth muscle cells due to elevated local production of angiotensin II and reactive 




The main function of the renin-angiotensin system (RAS) of mammals is to 
regulate blood pressure and electrolyte balance, and dysregulated activation of the 
RAS has been linked to the pathogenesis of different cardiovascular alterations, 
including hypertension, atherosclerosis, restenosis post-angioplasty, aortic 
aneurysm, heart attack, and hypertrophy of the left ventricle and vascular smooth 
muscle cells (VSMCs) [1, 2]. Key components of the RAS are renin and the renin-
like enzyme cathepsin D (CatD), which cleave angiotensinogen to produce 
angiotensin I (AngI); angiotensin converting enzyme (ACE), the carboxydipetidase 
that converts AngI into AngII, primarily in the lung; and AngII receptors [1, 2]. 
Adverse cardiovascular events have also been linked to deficiency of vitamin D 
(VitD) leading to reduced signaling through its receptor VDR, a member of the 
nuclear receptor superfamily that mediates the action of the active form of VitD3 
(1,25-dihydroxyvitamin D3, also called calcitriol) [3]. In addition to their implications 
in cardiovascular disease, both vitamin D/VDR and the RAS play important roles in 
physiological processes [2, 4]. 
The tissue distributions of VitD receptors and the RAS overlap almost exactly, and 
previous studies established functional relationships between the RAS and 
VitD/VDR systems [5]. For example, the plasma VitD level correlates inversely with 
plasma renin activity and blood pressure [6-8], and VitD supplementation can 
reduce blood pressure in hypertensive patients [9, 10]. The inverse relation 
between vitamin D and activity of the RAS could be at least partly explained by 
VitD /VDR–dependent suppression of renin transcription [11, 12]. In agreement 
with these findings, renin expression and plasma AngII production are elevated in 
VDR-null mice, correlating with the development of hypertension and cardiac 
hypertrophy and above-normal water intake independently of effects on the levels 
of blood calcium or parathyroid hormone [12]. Recent studies have improved our 
understanding of the crosstalk between VitD and the RAS, but many aspects of 
their complex interaction remain unknown [5]. 
In this issue of Atherosclerosis, Valcheva et al. [13] add new pieces to the puzzle 
of the VitD-RAS relationship. By analyzing primary cultures of wild-type and VDR-
null VSMCs, they demonstrate that VDR deficiency enhances production of AngII 
and reactive oxygen species (ROS), leading to premature cell senescence; these 
are characteristic features of the pathological vascular remodeling that occurs 
during atherosclerosis, hypertension and aging [14-16]. The authors first examined 
primary VSMCs for the expression of several factors involved in AngII-mediated 
signaling. They could not detect renin expression in wild-type and VDR-null 
VSMCs; however mutant VSMCs expressed high mRNA and protein levels of both 
the renin-like acid protease CatD and AngII type 1 receptor (AT1), and this 
correlated with a higher AngII level in the culture medium. Fukuda et al. were 
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similarly unable to detect renin in rat VSMCs and found that higher production of 
AngII in VSMCs from spontaneously hypertensive rats was due to increased CatD 
expression [17]. Collectively, the observations by Valcheva et al. suggest that VDR 
deficiency in VSMCs causes local RAS activation due at least partly to induction of 
CatD and AT1. VitD suppresses renin gene transcription by blocking the activity of 
the cyclic-AMP-response element (CRE) directly in the renin gene promoter [11]. 
Since the CatD promoter contains a putative CRE [18], the authors suggest that 
CatD may be subject to the same inhibitory regulation by VitD as renin. Testing this 
and other possible pathways is necessary in order to understand how VitD 
regulates CatD and AT1 expression, which may reveal new therapeutic targets. 
Cell senescence is activated upon tissue damage in diverse pathological contexts 
in response to different stimuli, such as DNA damage and telomere loss, 
derepression of CDKN2a, oncogenic signaling, inactivation of tumor suppressors, 
and accumulation of ROS [19]. Bearing in mind that systemic RAS activation 
augments ROS generation and VSMC senescence [15, 16], Valcheva and 
colleagues next examined the intracellular production of superoxide anions and the 
activity of senescence-associated-β-galactosidase (SA-β-GAL), the most widely 
used assay for cell senescence. Compared with wild-type cells, VDR-null VSMCs 
had higher levels of intracellular superoxide anion, and this was accompanied by a 
significant accumulation of cells with SA-β-GAL activity. This excess of ROS could 
be decreased by treatment with either pepstatin A (an inhibitor of aspartyl 
proteases, including CatD), losartan (an AT1 antagonist), or diphenyleneiodonium 
(an NADPH oxidase inhibitor), suggesting that the increment in VSMC free radical 
content induced by the lack of VitD is caused by elevated AngII/AT1-dependent 
activation of NADH oxidase. Importantly, treatment of VDR-null VSMCs with 
pepstatin A and the AT1 antagonist losartan over a period of 14 days in culture 
also prevented the accumulation of SA-β-GAL. Of note in this regard, increased 
VSMC senescence in low-density lipoprotein receptor-null mice lacking VDR is 
associated with augmented formation of atherosclerotic plaques, and inhibition of 
renin by aliskiren reduces atherosclerosis burden in these double-mutant mice, 
consistent with the idea that the RAS aggravates atherosclerosis in the absence of 
VDR at least partly by promoting cellular senescence [20].  
During active tissue repair, senescent cells arrest their own proliferation [19]. Using 
growth curve studies and cell-cycle analysis, Valcheva and colleagues found below 
normal proliferation rates in VDR-null VSMCs, while the proportion of dead cells 
was the same as in wild-type controls. Consistent with the observation that AngII 
enhances VSMC growth through AT1 receptor signaling [1], treatment with losartan 
significantly inhibited the proliferation of wild-type VSMCs. In contrast, in VDR-null 
VSMC cultures losartan inhibited SA-β-GAL activity and increased proliferation, in 
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agreement with the notion that VitD deficiency promotes senescence in VSMCs via 
increased AngII/AT1-dependent signaling. A key process in the regeneration of 
damaged tissues is the clearance of senescent cells through the recruitment of 
phagocytic immune cells [19]. Whether senescent VSMCs lacking VDR have an 
impaired capacity to induce their own elimination as a result of elevated AngII 
production and reduced recruitment of immune cells is an intriguing possibility that 
deserves further investigation.   
Valcheva and colleagues went on to elucidate the mechanisms underlying cell-
cycle arrest and senescence in VDR-null VSMCs, and found significantly elevated 
expression of p57Kip2, a cyclin-dependent kinase inhibitor capable of inhibiting the 
growth of healthy cells and cancer cells [21]. The protection against senescence in 
VDR-null VSMCs achieved by pharmacological inhibition of CatD and AT1 was 
accompanied by reduced levels of p57Kip2 mRNA. These results suggest that 
higher expression of the cell-cycle inhibitor p57Kip2 is implicated in the induction of 
growth arrest and senescence in VSMCs with defective VitD signaling. Additional 
studies are warranted to examine the mechanisms regulating p57Kip2 in this 
context, and to assess whether VitD signaling affects the expression or activity of 
other tumor suppressors known to promote cellular senescence, such as p16Ink4a, 
ARF, p53, p21Cip1, p15 Ink4a, p27Kip1 and hypophosphorylated retinoblastoma protein 
[19]. Particularly interesting candidates are p21Cip1, which is required for AngII-
induced premature senescence of VSMCs and atherosclerosis development [15], 
and p27Kip1, an important regulator of VSMC phenotype and vascular occlusive 
lesion development [22] that is modulated by both AngII [23, 24] and VitD [25, 26]. 
Two other notable observations are that AngII accelerates telomere attrition and 
induces DNA damage in human VSMCs via AT1 receptor-mediated induction of 
ROS [27] and that, conversely, treatment with vitamin D reduces oxidative stress 
damage and chromosomal aberrations and prevents telomere shortening in animal 
models and a variety of cell types [28, 29]. In light of these observations, future 
studies are warranted to examine whether the crosstalk between VitD/VDR and the 
RAS involves the regulation of key components of the DNA damage response and 
telomere function. 
Valcheva and colleagues confirmed some of their in vitro findings by demonstrating 
higher CatD, AT1 and p57Kip2 protein levels in aortic tissue of 6-month-old VDR-null 
mice, as assessed by western blot and immunohistochemical analysis. Although 
the results of these mouse studies are encouraging, additional work is needed to 
ascertain whether defective VitD signaling leads to increased local production of 
AngII and ROS and accumulation of senescent VSMCs in the artery wall. Since the 
aged vasculature is characterized by increased AngII and ROS production and the 
accumulation of senescent cells [16], studies are warranted in older wild-type and 
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VDR-null mice (18-24 months old), which may reveal an age-associated 
exacerbation of pathological responses in the absence of VitD signaling.  
Valcheva and colleagues’ study shows for the first time that defective VitD 
signaling can promote vascular damage by inducing premature VSMC senescence 
as a result of elevated local production of AngII and ROS and upregulation of the 
tumor suppressor p57Kip2. As recognized by the authors, it is difficult to extrapolate 
the results of cellular and animal models to humans; however, their findings 
uncover new regulatory circuits which might be important in a range of 
degenerative diseases that are reciprocally affected by VitD/VDR and the RAS, 
and that therefore might benefit from combined VitD supplementation and RAS 
inactivation, such as cardiovascular and renal disease, obesity, and diabetes.  
 
 
CONFLICT OF INTEREST 




I thank Beatriz Dorado for critical reading of the manuscript and Simon Bartlett for 
English editing. Work in the author’s laboratory is supported by grants from the 
Ministerio de Economía y Competitividad (MINECO) (grant No. SAF2013-46663-
R), Fondo Europeo de Desarrollo Regional (FEDER), Instituto de Salud Carlos III 
(grant No. RD12/0042/0028), European Union FP7 (Liphos, grant No. 317916), 
and The Progeria Research Foundation (Innovator Award 2012, and Established 






[1] Touyz, RM and Schiffrin, EL. Signal transduction mechanisms mediating the 
physiological and pathophysiological actions of angiotensin II in vascular smooth 
muscle cells. Pharmacol Rev 2000;52:639-72. 
[2] Crowley, SD and Coffman, TM. Recent advances involving the renin-angiotensin 
system. Exp Cell Res 2012;318:1049-56. 
[3] Wang, TJ, Pencina, MJ, Booth, SL, Jacques, PF, Ingelsson, E, Lanier, K, et al. 
Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-
11. 
[4] Goltzman, D, Hendy, GN and White, JH. Vitamin D and its receptor during late 
development. Biochim Biophys Acta 2014;(in press). 
[5] Ferder, M, Inserra, F, Manucha, W and Ferder, L. The world pandemic of vitamin D 
deficiency could possibly be explained by cellular inflammatory response activity 
induced by the renin-angiotensin system. Am J Physiol Cell Physiol 
2013;304:C1027-39. 
[6] Burgess, ED, Hawkins, RG and Watanabe, M. Interaction of 1,25-dihydroxyvitamin D 
and plasma renin activity in high renin essential hypertension. Am J Hypertens 
1990;3:903-5. 
[7] Kristal-Boneh, E, Froom, P, Harari, G and Ribak, J. Association of calcitriol and 
blood pressure in normotensive men. Hypertension 1997;30:1289-94. 
[8] Lind, L, Hanni, A, Lithell, H, Hvarfner, A, Sorensen, OH and Ljunghall, S. Vitamin D 
is related to blood pressure and other cardiovascular risk factors in middle-aged 
men. Am J Hypertens 1995;8:894-901. 
[9] Lind, L, Wengle, B, Wide, L and Ljunghall, S. Reduction of blood pressure during 
long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma 
renin activity and calcium status. A double-blind, placebo-controlled study. Am J 
Hypertens 1989;2:20-5. 
[10] Pfeifer, M, Begerow, B, Minne, HW, Nachtigall, D and Hansen, C. Effects of a short-
term vitamin D(3) and calcium supplementation on blood pressure and parathyroid 
hormone levels in elderly women. J Clin Endocrinol Metab 2001;86:1633-7. 
[11] Yuan, W, Pan, W, Kong, J, Zheng, W, Szeto, FL, Wong, KE, et al. 1,25-
dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of 
the cyclic AMP response element in the renin gene promoter. J Biol Chem 
2007;282:29821-30. 
[12] Li, YC, Kong, J, Wei, M, Chen, ZF, Liu, SQ and Cao, LP. 1,25-Dihydroxyvitamin D(3) 
is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 
2002;110:229-38. 
[13] Valcheva, P, Cardus, A, Panizo, S, Parisi, E, Bozic, M, Lopez Novoa, JM, et al. Lack 
of vitamin D receptor causes stress-induced premature senescence in vascular 
smooth muscle cells through enhanced local angiotensin-II signals. Atherosclerosis 
2014;235:247-55. 




[15] Kunieda, T, Minamino, T, Nishi, J, Tateno, K, Oyama, T, Katsuno, T, et al. 
Angiotensin II induces premature senescence of vascular smooth muscle cells and 
accelerates the development of atherosclerosis via a p21-dependent pathway. 
Circulation 2006;114:953-60. 
[16] Wang, M, Monticone, RE and Lakatta, EG. Arterial aging: a journey into subclinical 
arterial disease. Curr Opin Nephrol Hypertens 2010;19:201-7. 
[17] Fukuda, N, Satoh, C, Hu, WY, Soma, M, Kubo, A, Kishioka, H, et al. Production of 
angiotensin II by homogeneous cultures of vascular smooth muscle cells from 
spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1999;19:1210-7. 
[18] Hetman, M, Perschl, A, Saftig, P, Von Figura, K and Peters, C. Mouse cathepsin D 
gene: molecular organization, characterization of the promoter, and chromosomal 
localization. DNA Cell Biol 1994;13:419-27. 
[19] Muñoz-Espín, D and Serrano, M. Cellular senescence: from physiology to pathology. 
Nat Rev Mol Cell Biol 2014;15:482-96. 
[20] Szeto, FL, Reardon, CA, Yoon, D, Wang, Y, Wong, KE, Chen, Y, et al. Vitamin D 
receptor signaling inhibits atherosclerosis in mice. Mol Endocrinol 2012;26:1091-101. 
[21] Tesio, M and Trumpp, A. Breaking the cell cycle of HSCs by p57 and friends. Cell 
Stem Cell 2011;9:187-92. 
[22] Andrés, V and Castro, C. Antiproliferative strategies for the treatment of vascular 
proliferative disease. Curr Vasc Pharmacol 2003;1:85-98. 
[23] Braun-Dullaeus, RC, Mann, MJ, Ziegler, A, von der Leyen, HE and Dzau, VJ. A 
novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-
stimulated vascular smooth muscle cell hypertrophy. J Clin Invest 1999;104:815-23. 
[24] Servant, MJ, Coulombe, P, Turgeon, B and Meloche, S. Differential regulation of 
p27(Kip1) expression by mitogenic and hypertrophic factors: Involvement of 
transcriptional and posttranscriptional mechanisms. J Cell Biol 2000;148:543-56. 
[25] Chiang, KC and Chen, TC. Vitamin D for the prevention and treatment of pancreatic 
cancer. World J Gastroenterol 2009;15:3349-54. 
[26] Johnson, CS, Muindi, JR, Hershberger, PA and Trump, DL. The antitumor efficacy of 
calcitriol: preclinical studies. Anticancer Res 2006;26:2543-9. 
[27] Herbert, KE, Mistry, Y, Hastings, R, Poolman, T, Niklason, L and Williams, B. 
Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in 
cultured human vascular smooth muscle cells via telomere-dependent and 
independent pathways. Circ Res 2008;102:201-8. 
[28] Dixon, KM, Sequeira, VB, Camp, AJ and Mason, RS. Vitamin D-fence. Photochem 
Photobiol Sci 2010;9:564-70. 
[29] Nair-Shalliker, V, Armstrong, BK and Fenech, M. Does vitamin D protect against 







Model of AngII-dependent induction of premature VSMC senescence upon 
disruption of VDR. The model is based on the results reported in this issue of 
Atherosclerosis by Valcheva et al. [13]. Primary cultures of wild-type VSMCs (top), 
with intact VitD/VDR signaling, exhibit repressed transcription of AngII type 1 
receptor (AT1) and cathepsin D (CatD, which converts angiotensinogen into AngI), 
and low production of AngII. In contrast, primary VDR-null VSMCs (bottom) have 
high expression of CatD and AT1 mRNA and protein and elevated AngII 
production. This is accompanied by activation of NADPH oxidase and high ROS 
production leading to elevated p57Kip2 mRNA and protein levels and the premature 
onset of VSMC senescence. Red text indicates factors that are upregulated in 
VDR-null VSMCs and green text drugs used by Valcheva and colleagues to block 
different steps in the pathways that link VDR deficiency to AngII-AT1-induced ROS 
production and VSMC senescence. Higher expression levels of the AngII signaling 
components CatD and AT1 and the growth suppressor p57Kip2 were also observed 
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